@article{8f369d3a42ae4bad9956aee548cb755a,
title = "Latent Ornstein-Uhlenbeck models for Bayesian analysis of multivariate longitudinal categorical responses",
abstract = "We propose a Bayesian latent Ornstein-Uhlenbeck (OU) model to analyze unbalanced longitudinal data of binary and ordinal variables, which are manifestations of fewer continuous latent variables. We focus on the evolution of such latent variables when they continuously change over time. Existing approaches are limited to data collected at regular time intervals. Our proposal makes use of an OU process for the latent variables to overcome this limitation. We show that assuming real eigenvalues for the drift matrix of the OU process, as is frequently done in practice, can lead to biased estimates and/or misleading inference when the true process is oscillating. In contrast, our proposal allows for both real and complex eigenvalues. We illustrate our proposed model with a motivating dataset, containing patients with amyotrophic lateral sclerosis disease. We were interested in how bulbar, cervical, and lumbar functions evolve over time.",
keywords = "Bayesian modeling, Ornstein-Uhlenbeck process, Latent variable, Multivariate longitudinal data analysis, Oscillating and nonoscillating processes",
author = "Tran, {Trung Dung} and Emmanuel Lesaffre and Geert Verbeke and Joke Duyck",
note = "Funding Information: The authors thank Professor Philip Van Damme (VIB-KU Leuven), the two anonymous referees, and the associate editor for their constructive comments. The authors obtain financial support from the funding C24/15/034 of KU Leuven, Belgium. ALS data used in the preparation of this article were obtained from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Database. In 2011, Prize4Life, in collaboration with the Northeast ALS Consortium, and with funding from the ALS Therapy Alliance, formed the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) Consortium. The data available in the PRO-ACT Database has been volunteered by PRO-ACT Consortium members. As such, the following organizations and individuals within the PRO-ACT Consortium contributed to the design and implementation of the PRO-ACT Database and/or provided data, but did not participate in the analysis of the data or the writing of this report: Neurological Clinical Research Institute, MGH; Northeast ALS Consortium; Novartis; Prize4Life Israel; Regeneron Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries, Ltd. Funding Information: The authors thank Professor Philip Van Damme (VIB‐KU Leuven), the two anonymous referees, and the associate editor for their constructive comments. The authors obtain financial support from the funding C24/15/034 of KU Leuven, Belgium. ALS data used in the preparation of this article were obtained from the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) Database. In 2011, Prize4Life, in collaboration with the Northeast ALS Consortium, and with funding from the ALS Therapy Alliance, formed the Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) Consortium. The data available in the PRO‐ACT Database has been volunteered by PRO‐ACT Consortium members. As such, the following organizations and individuals within the PRO‐ACT Consortium contributed to the design and implementation of the PRO‐ACT Database and/or provided data, but did not participate in the analysis of the data or the writing of this report: Neurological Clinical Research Institute, MGH; Northeast ALS Consortium; Novartis; Prize4Life Israel; Regeneron Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries, Ltd. Publisher Copyright: {\textcopyright} 2020 The International Biometric Society",
year = "2021",
month = jun,
doi = "10.1111/biom.13292",
language = "English",
volume = "77",
pages = "689--701",
journal = "Biometrics",
issn = "0006-341X",
publisher = "Wiley-Blackwell",
number = "2",
}